Chiglitazar - Chipscreen Biosciences

Drug Profile

Chiglitazar - Chipscreen Biosciences

Alternative Names: CS-038

Latest Information Update: 28 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chipscreen Biosciences
  • Class Antidementias; Antihyperglycaemics; Carbazoles; Propionic acids; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Type 2 diabetes mellitus
  • No development reported Parkinson's disease

Most Recent Events

  • 28 Sep 2018 No recent reports of development identified for preclinical development in Parkinson's-disease in China (PO)
  • 01 Jul 2018 Chipscreen Biosciences completes a phase III trial for Type-2 diabetes mellitus in China (PO) (NCT02121717)
  • 01 Jul 2018 Chipscreen Biosciences completes the phase III CMAS trial for Type-2 diabetes mellitus in China (NCT02173457)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top